Croatian pharmaceuticals producer Jadran Galenski Laboratorij (JGL) said it completed a 53 million euro ($57 million) investment project, boosting its production and research capacity.

The project, named INTEGRA, included construction of high-tech facilities on two locations near Rijeka, and took three years to complete, the company said.

Thanks to a new line installed for sterile production of drop solutions and spays, the company’s capacity in that segment has increased 60%. The company’s new production facility covers 3,250 square metres and its new laboratories spread on 2,450 square metres.

As part of the investment project, it also presented a new 20,000 square metres logistics distribution center with a capacity of 17,500 pallets.

Founded in 1991, JGL is one of the largest drug makers in Croatia, specialised in the production of sterile nose, eye and ear drop solutions.